Article
Determination of Slow-binding HDAC Inhibitor Potency and Subclass Selectivity
2021-12-18
Abstract excerpt
<h4>ABSTRACT</h4> Histone deacetylases (HDACs) 1–3 regulate chromatin structure and gene expression. These three enzymes are targets for cancer chemotherapy and are studied for the treatment of immune disorders and neurodegeneration, but there is a lack of selective pharmacological tool compounds to unravel their individual roles. Potent inhibitors of HDACs 1–3 often display slow-binding kinetics, which causes a...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 306fbb4c-0c91-577d-8c26-1116b4ca6cf7
- DOI
- 10.1101/2021.12.18.473277
